^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DDX5 degrader

    Related drugs:
    22d
    FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5. (PubMed, Int J Mol Sci)
    Furthermore, FL118 potently induced apoptosis not only in Ba/F3 cells expressing BCR-ABL, but also in those expressing the BCR-ABL T315I mutant, which is resistant to BCR-ABL inhibitors. Collectively, these results revealed that DDX5 is a critical therapeutic target in CML and that FL118 is an effective candidate compound for the treatment of BCR-ABL inhibitor-resistant CML.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • DDX5 (DEAD-Box Helicase 5)
    |
    BIRC5 expression • BCR expression
    |
    FL118
    27d
    FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: May 2027 --> Oct 2027 | Initiation date: Apr 2024 --> Oct 2024 | Trial primary completion date: May 2027 --> Oct 2027
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    FL118